Vanda Pharmaceuticals GAAP EPS of $0.06, revenue of $65.32M

  • Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q3 GAAP EPS of $0.06.
  • Revenue of $65.32M (-6.8% Y/Y).
  • Cash, cash equivalents and marketable securities (Cash) was $454.8 million as of September 30, 2022, representing an increase to Cash of $13.9 million, or 3%, compared to June 30, 2022.
  • Revised 2022 Guidance: Revenue expected between $240 to $270 million, vs. prior guidance range of $240 to $280 million

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.